APEX is the first to launch and dose a take-home microdose psilocybin clinical trial, with the largest of its kind approved and beginning recruitment Q2 2023.
8-Year Data Exclusivity
Following commercial approval, APEX drug assets have data protection for 8 years in Canada.
Optimized Dosing Options and Clinical Pipeline
Two drug assets in the pipeline have the potential to be optimized for severity across indications.
Decades of healthcare, clinical and pharmaceutical experience with representation from the Veteran community in the C-suite and past corporate experience with Johnson & Johnson, Roche, GSK, Lilly, McKesson, Tilay, Sharp, and Canaccord.
Pre-DIN SAP Macro-Dose
In clinic macro-dose with assisted psychotherapy through strategic partnerships utilizing Veteran focused clinics with Nationwide footprints. Pre-Drug Identification Number (DIN) revenue created by sales and insurance coverage for Canadian Armed Forces and RCMP Veterans.
Secure DIN by successful statistically powered clinical program for APEX-52 take-home microdose drug asset and APEX-90 macro-dose drug asset achieving regulatory approval in Canada, USA, Europe and Australia for broad commercial sales. Canadian Armed Forces and RCMP Veteran insurance programs from SAP macro-dose initiative to inform broader reimbursement.